Author:
Nutt J E,Lazarowicz H P,Mellon J K,Lunec J
Publisher
Springer Science and Business Media LLC
Reference38 articles.
1. Anderson NG, Ahmad T, Chan K, Dobson R, Bundred NJ (2001) ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression. Int J Cancer 94: 774–782
2. Baselga J, Averbuch SD (2000) ZD1839 (‘Iressa’) as an anticancer agent. Drugs 60: 33–40
3. Benbow U, Brinckerhoff CE (1997) The AP-1 site and MMP gene regulation: what is all the fuss about? Matrix Biol 15: 519–526
4. Booth C, Harnden P, Trejdosiewicz LK, Scriven S, Selby PJ, Southgate J (1997) Stromal and vascular invasion in an human in vitro bladder cancer model. Lab Invest 76: 843–857
5. Brotherick I, Lennard TWJ, Wilkinson SE, Cook S, Angus B, Shenton BK (1994) Flow cytometric method for the measurement of epidermal growth-factor receptor and comparison with the radio-ligand binding assay. Cytometry 16: 262–269
Cited by
47 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献